Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 5.300-5.400 for the period, compared to the consensus earnings per share estimate of 5.230. The company issued revenue guidance of $4.6 billion-$4.6 billion, compared to the consensus revenue estimate of $4.6 billion.

Illumina Stock Performance

NASDAQ ILMN traded up $10.27 on Thursday, reaching $205.09. The stock had a trading volume of 2,763,533 shares, compared to its average volume of 1,646,504. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a fifty day moving average of $175.49 and a two-hundred day moving average of $146.83. Illumina has a 1-year low of $88.00 and a 1-year high of $205.47. The company has a market cap of $31.03 billion, a P/E ratio of 37.29, a price-to-earnings-growth ratio of 2.88 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina will post 5.22 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ILMN shares. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Piper Sandler increased their price target on Illumina from $170.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Canaccord Genuity Group upped their target price on Illumina from $140.00 to $190.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a report on Monday, July 6th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $156.88.

Insiders Place Their Bets

In related news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,003,769 shares of company stock valued at $155,710,908 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 beat expectations: Revenue rose approximately 9.4% year over year to $1.16 billion, exceeding the $1.13 billion consensus estimate. Non-GAAP diluted EPS was $1.31, above expectations of about $1.23, while GAAP diluted EPS reached $1.35. Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised
• Positive Sentiment: Improved operating performance: Gross profit increased 10.8% to $770 million, and operating profit rose 14.5% to $245 million. Illumina reported a 21.1% GAAP operating margin and a 22.5% non-GAAP operating margin, supporting the case for expanding profitability. Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
• Positive Sentiment: FY 2026 outlook was favorable: Adjusted EPS guidance was set at $5.30-$5.40, above the roughly $5.23 analyst consensus. Revenue guidance of approximately $4.6 billion, with a midpoint near $4.62 billion, was also modestly ahead of expectations. Illumina Surprises With Q2 Sales and Outlook
• Positive Sentiment: Strategic validation: Eli Lilly joined Illumina’s Billion Cell Atlas alliance as a foundational participant, potentially strengthening Illumina’s position in genomic data and AI-driven drug discovery. Eli Lilly Joins Illumina’s Billion Cell Atlas
• Neutral Sentiment: Reported insider trading data showed substantially more selling than buying over the past six months, although the activity was not directly tied to the quarterly announcement and may have limited near-term relevance.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC bought a new position in shares of Illumina in the 2nd quarter valued at $621,000. Siemens Fonds Invest GmbH grew its position in Illumina by 22.4% during the 4th quarter. Siemens Fonds Invest GmbH now owns 4,662 shares of the life sciences company’s stock worth $619,000 after acquiring an additional 854 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in Illumina in the 4th quarter worth about $590,000. Kestra Advisory Services LLC increased its holdings in Illumina by 9.3% in the 4th quarter. Kestra Advisory Services LLC now owns 3,708 shares of the life sciences company’s stock worth $486,000 after purchasing an additional 316 shares in the last quarter. Finally, Lido Advisors LLC raised its position in Illumina by 5.2% in the fourth quarter. Lido Advisors LLC now owns 3,490 shares of the life sciences company’s stock valued at $458,000 after purchasing an additional 174 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.